PMC2 ESTIMATING COST-EFFECTIVENESS BASED ON RESULTS OF UNCONTROLLED CLINICAL TRIALS- OFATUMUMAB FOR THE TREATMENT OF FLUDARABINE- AND ALEMTUZUMAB-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA

Nov 1, 2010, 00:00
10.1016/S1098-3015(11)72285-9
https://www.valueinhealthjournal.com/article/S1098-3015(11)72285-9/fulltext
Title : PMC2 ESTIMATING COST-EFFECTIVENESS BASED ON RESULTS OF UNCONTROLLED CLINICAL TRIALS- OFATUMUMAB FOR THE TREATMENT OF FLUDARABINE- AND ALEMTUZUMAB-REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)72285-9&doi=10.1016/S1098-3015(11)72285-9
First page : A328
Section Title : RESEARCH POSTER ABSTRACTS
Open access? : No
Section Order : 444
Categories :
Tags :
Regions :
ViH Article Tags :